Omalizumab in the treatment of eosinophilic esophagitis and food allergy
European Journal of Pediatrics, 08/29/2011
Rocha R et al. – Omalizumab may improve the quality of life of patients with severe food allergy by improving symptoms, but it does not appear to change endoscopic and histological features of eosinophilic esophagitis in a short follow–up.
Omalizumab is currently used in severe asthma and has been tried in other allergic disorders.
Patients significantly improved in the reported symptoms.
However, no improvement was seen regarding esophageal endoscopy and histology.
Given the poor histological and endoscopy response, eosinophilic esophagitis persistence is unlikely to be IgE dependent.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.